Tools to accelerate falciparum malaria elimination in Cambodia: a meeting report.
Cambodia
Case detection
Forest malaria
Malaria elimination
Mass drug administration
Plasmodium falciparum
Prophylaxis
Screening and treatment
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
16
02
2020
accepted:
20
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Cambodia targets malaria elimination by 2025. Rapid elimination will depend on successfully identifying and clearing malaria foci linked to forests. Expanding and maintaining universal access to early diagnosis and effective treatment remains the key to malaria control and ultimately malaria elimination in the Greater Mekong Subregion (GMS) in the foreseeable future. Mass Drug Administration (MDA) holds some promise in the rapid reduction of Plasmodium falciparum infections, but requires considerable investment of resources and time to mobilize the target communities. Furthermore, the most practical drug regimen for MDA in the GMS-three rounds of DHA/piperaquine-has lost some of its efficacy. Mass screening and treatment benefits asymptomatic P. falciparum carriers by clearing chronic infections, but in its current form holds little promise for malaria elimination. Hopes that "highly sensitive" diagnostic tests would provide substantial advances in screen and treat programmes have been shown to be misplaced. To reduce the burden on P. falciparum and Plasmodium vivax infections in people working in forested areas novel approaches to the use of malaria prophylaxis in forest workers should be explored. During an October 2019 workshop in Phnom Penh researchers and policymakers reviewed evidence of acceptability, feasibility and effectiveness of interventions to target malaria foci and interrupt P. falciparum transmission and discussed operational requirements and conditions for programmatic implementation.
Identifiants
pubmed: 32293452
doi: 10.1186/s12936-020-03197-6
pii: 10.1186/s12936-020-03197-6
pmc: PMC7161105
doi:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/T003553/1
Pays : United Kingdom
Références
PLoS One. 2019 Mar 25;14(3):e0214280
pubmed: 30908523
PLoS Med. 2016 Jan 19;13(1):e1001942
pubmed: 26783752
Malar J. 2016 Nov 2;15(1):523
pubmed: 27806717
Am J Trop Med Hyg. 2020 Feb;102(2):307-309
pubmed: 31820711
Trials. 2018 Oct 16;19(1):558
pubmed: 30326952
BMC Health Serv Res. 2017 May 8;17(1):335
pubmed: 28482899
Glob Health Action. 2017;10(1):1366136
pubmed: 28914184
Malar J. 2016 Aug 30;15(1):440
pubmed: 27577697
Glob Health Sci Pract. 2018 Jun 29;6(2):384-389
pubmed: 29875157
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
J Infect Dis. 2016 Apr 15;213(8):1322-9
pubmed: 26681777
PLoS Negl Trop Dis. 2019 Aug 5;13(8):e0007606
pubmed: 31381570
Trends Parasitol. 2003 Oct;19(10):452-60
pubmed: 14519583
PLoS One. 2016 Jul 14;11(7):e0158737
pubmed: 27415623
Lancet Infect Dis. 2016 Oct;16(10):1169-1177
pubmed: 27371977
Am J Trop Med Hyg. 2015 Jul;93(1):125-134
pubmed: 26013371
Trends Parasitol. 2019 Jun;35(6):388-398
pubmed: 31076353
Lancet Infect Dis. 2019 Sep;19(9):943-951
pubmed: 31345709
Lancet. 2018 Apr 7;391(10128):1378-1390
pubmed: 29606364
Malar J. 2019 Feb 1;18(1):32
pubmed: 30709399
Front Public Health. 2017 Sep 26;5:262
pubmed: 29034229
PLoS Med. 2014 May 13;11(5):e1001642
pubmed: 24824170
Malar J. 2017 Oct 23;16(1):424
pubmed: 29061133
Malar J. 2018 Jan 10;17(1):22
pubmed: 29321011
Malar J. 2016 Sep 01;15(1):446
pubmed: 27585957
Trop Med Int Health. 2005 Mar;10(3):251-62
pubmed: 15730510
Malar J. 2016 May 10;15(1):271
pubmed: 27165296
Expert Rev Anti Infect Ther. 2015 Jun;13(6):715-30
pubmed: 25831482
Clin Infect Dis. 2018 Aug 31;67(6):817-826
pubmed: 29522113
J Clin Microbiol. 2018 Jul 26;56(8):
pubmed: 29898998
Lancet Infect Dis. 2016 Feb;16(2):189-98
pubmed: 26601738
Trop Med Health. 2019 Jan 25;47:10
pubmed: 30700969
Malar J. 2019 Jan 23;18(1):20
pubmed: 30674319
Malar J. 2016 May 20;15(1):282
pubmed: 27206729
Gates Open Res. 2019 Dec 17;3:1730
pubmed: 32118199
Malar J. 2019 Sep 14;18(1):311
pubmed: 31521176
Malar J. 2017 Nov 28;16(1):483
pubmed: 29183370
PLoS Med. 2014 Jan 28;11(1):e1001594
pubmed: 24492859
Malar J. 2013 Nov 15;12:418
pubmed: 24228846
Lancet Infect Dis. 2020 Apr;20(4):498-508
pubmed: 31948767
Malar J. 2015 Sep 29;14:376
pubmed: 26416075
PLoS Med. 2019 Feb 15;16(2):e1002745
pubmed: 30768615
Heliyon. 2017 Nov 20;3(11):e00447
pubmed: 29202107
Am J Trop Med Hyg. 2018 Jan;98(1):100-104
pubmed: 29165227
PLoS Med. 2012;9(11):e1001339
pubmed: 23152723
Malar J. 2016 Aug 26;15(1):434
pubmed: 27562347
Clin Infect Dis. 2018 May 2;66(10):1610-1617
pubmed: 29361021
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Lancet. 2018 May 12;391(10133):1916-1926
pubmed: 29703425
PLoS One. 2012;7(10):e45797
pubmed: 23049687
Malar J. 2013 Oct 11;12:363
pubmed: 24119916
PLoS Biol. 2007 Mar;5(3):e42
pubmed: 17311470
Malar J. 2018 Jan 9;17(1):15
pubmed: 29316932
Lancet. 2000 Nov 4;356(9241):1560-4
pubmed: 11075770
Malar J. 2017 Oct 13;16(1):412
pubmed: 29029614
Lancet. 2020 Mar 11;:
pubmed: 32171078
Am J Trop Med Hyg. 2019 May;100(5):1170-1178
pubmed: 30860021
Glob Health Sci Pract. 2016 Dec 28;4(4):511-513
pubmed: 27965265
Malar J. 2014 Sep 30;13:385
pubmed: 25266007
Malar J. 2013 Oct 11;12:364
pubmed: 24119994
Wellcome Open Res. 2019 May 31;4:87
pubmed: 31289754